{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:11:33Z","timestamp":1792174293889,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.jhep.2014.07.022","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T21:17:21Z","timestamp":1406150241000},"page":"1238-1246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":138,"title":["A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection"],"prefix":"10.1016","volume":"61","author":[{"given":"Andrew J.","family":"Muir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Everson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Ghalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart C.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Greenbloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hassanein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hillson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Arantxa","family":"Horga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira M.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennox","family":"Jeffers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lawitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lueth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Rodriguez-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Rustgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Shemanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subasree","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo E.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Lopez-Talavera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2014.07.022_b0005","unstructured":"Vertex Pharmaceuticals I. INCIVEK\u2122 (telaprevir) Prescribing Information; 2012."},{"key":"10.1016\/j.jhep.2014.07.022_b0010","unstructured":"Merck Sharp & Dohme Corp. VICTRELISTM (boceprevir) [package insert]; 2013."},{"key":"10.1016\/j.jhep.2014.07.022_b0015","unstructured":"Janssen Therapeutics. OLYSIO\u2122 (simeprevir) Prescribing Information; 2014."},{"key":"10.1016\/j.jhep.2014.07.022_b0020","unstructured":"Food and Drug Administration. SOVALDI\u2122 (sofosbuvir) Prescribing Information; 2014."},{"key":"10.1016\/j.jhep.2014.07.022_b0025","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2011.05.032","article-title":"Gaps in the achievement of effectiveness of HCV treatment in national VA practice","volume":"56","author":"Kramer","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.022_b0030","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/hep.26246","article-title":"A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care","volume":"57","author":"McGowan","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.022_b0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.022_b0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.022_b0045","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2008.11.006","article-title":"Ribavirin: current role in the optimal clinical management of chronic hepatitis C","volume":"50","author":"Reddy","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.022_b0050","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0301-472X(99)00109-5","article-title":"Signaling pathways activated by interferons","volume":"27","author":"Platanias","year":"1999","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jhep.2014.07.022_b0055","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.022_b0060","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.022_b0065","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.022_b0070","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.022_b0075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/ni873","article-title":"IL-28, IL-29 and their class II cytokine receptor IL-28R","volume":"4","author":"Sheppard","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2014.07.022_b0080","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/ni875","article-title":"IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex","volume":"4","author":"Kotenko","year":"2003","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2014.07.022_b0085","doi-asserted-by":"crossref","first-page":"32269","DOI":"10.1074\/jbc.M404789200","article-title":"Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29\/interferon-lambda 1: similarities with type I interferon signaling","volume":"279","author":"Dumoutier","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2014.07.022_b0090","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1128\/JVI.02438-06","article-title":"Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases","volume":"81","author":"Zhou","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.022_b0095","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1128\/JVI.80.9.4501-4509.2006","article-title":"Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo","volume":"80","author":"Ank","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2014.07.022_b0100","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.21312","article-title":"Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes","volume":"44","author":"Doyle","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.022_b0105","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.4049\/jimmunol.1102038","article-title":"Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells","volume":"189","author":"Yin","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2014.07.022_b0110","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.23743","article-title":"Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection","volume":"52","author":"Muir","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.022_b0115","unstructured":"Food and Drug Administration. Copegus\u2122 (ribavirin) label 2010; 2010: <http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021511s020lbl.pdf>."},{"key":"10.1016\/j.jhep.2014.07.022_b0120","unstructured":"Food and Drug Administration. PEGASYS (peginterferon alfa-2a) label 2002; 2012."},{"key":"10.1016\/j.jhep.2014.07.022_b0125","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","article-title":"Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics","volume":"131","author":"Marcello","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.022_b0130","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4161\/cbt.7.7.6192","article-title":"IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK\/STAT signaling activity","volume":"7","author":"Maher","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.jhep.2014.07.022_b0135","doi-asserted-by":"crossref","first-page":"e22200","DOI":"10.1371\/journal.pone.0022200","article-title":"USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response","volume":"6","author":"Francois-Newton","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2014.07.022_b0140","first-page":"S438","article-title":"Sustained virologic response (SVR12) in HCV genotype 1 patients receiving peginterferon lambda in combination with ribavirin and either daclatasvir or asunaprevir: interim results from the D-LITE study","volume":"7","author":"Vierling","year":"2013","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2014.07.022_b0145","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2014.07.022_b0150","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2036.2008.03763.x","article-title":"Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis","volume":"28","author":"Andriulli","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2014.07.022_b0155","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","article-title":"Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus","volume":"139","author":"Thompson","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.022_b0160","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhep.2014.07.022_b0165","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2011.03.006","article-title":"IL28B single nucleotide polymorphisms in the treatment of hepatitis C","volume":"55","author":"Lange","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.022_b0170","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","article-title":"Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3","volume":"40","author":"Zeuzem","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.022_b0175","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/hep.25892","article-title":"High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials","volume":"56","author":"Marcellin","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.022_b0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection","volume":"55","author":"European Association for the Study of the Liver","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.022_b0185","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/he.2000.5789","article-title":"Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage","volume":"31","author":"De Franceschi","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.022_b0190","first-page":"993A","article-title":"Pegylated interferon lambda ameliorates ribavirin (RBV)-induced anemia in HCV patients by maintaining compensatory erythropoiesis: analysis of EMERGE phase 2b results through week 12 [Abstract]","volume":"54","author":"Everson","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.022_b0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2006.10.008","article-title":"Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a\/ribavirin treatment","volume":"5","author":"Reddy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2014.07.022_b0200","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1053\/j.gastro.2013.07.051","article-title":"Effects of ribavirin dose reduction vs. erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection \u2013 A randomized trial","volume":"145","author":"Poordad","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2014.07.022_b0205","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2014.07.022_b0210","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2014.07.022_b0215","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1373\/clinchem.2006.070961","article-title":"A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C","volume":"52","author":"Ngo","year":"2006","journal-title":"Clin Chem"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814005212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827814005212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:32:58Z","timestamp":1759174378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827814005212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0168827814005212"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2014.07.022","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718509416.793497945","asserted-by":"object"}]},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2014.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}